Stories from people navigating insulin therapy — diagnosis, treatment, caregiving, and the ordinary days in between.
3 stories
Endocrinology & Metabolism
FDA approval of insulin efsitora alfa-gobe creates a weekly basal insulin option for adults with type 2 diabetes, making treatment burden, hypoglycemia risk and follow-up capacity central to selection.
Rayan Salih · November 2, 2026 · 7 min
Endocrinology & Metabolism
ACHIEVE-5 reports better glycemic control and weight outcomes without more hypoglycemia when oral orforglipron is added to titrated insulin glargine, but the numerical results are essential to judge clinical value.
Dr. Abu Bakar · 6 min read
Endocrinology & Metabolism
REIMAGINE 3 found glycemic and weight benefits when cagrilintide-semaglutide was added to basal insulin in adults with type 2 diabetes. Hypoglycemia remains central to interpreting treatment escalation.
Dr. Abu Bakar · 6 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.